The present Competitive Intelligence Report about Notch Pathway Inhibitors provides a competitor evaluation in the field of molecules targeting Notch via gamma-secretase or its vascular ligand delta-like ligand-4 (DLL4) as of February 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The Notch signaling pathway has been found to play central roles in humans in stem cell maintenance, cell fate decisions, and in cancer as well. Notch family members are being revealed as oncogenes in an ever-increasing number of cancers. Notch signaling is also thought to be important for the maintenance of cancer stem cell populations in tumors. Cancer stem cells may cause tumor metastasis and relapse following anti-tumor treatments by regenerating the tumor tissue. Eradication of cancer stem cells may lead to increased survival in cancer patients.
First generation Notch inhibitors have entered clinical testing. Use of gamma secretase inhibitors may be associated with gastro-intestinal on-target side effects such as diarrhea. Targeting the vascular ligand of Notch (delta-like ligand 4, DLL4)by antibodies may offer tremendous promise as novel anti-tumor agents. At present, five different constructs targeting Notch/DLL4 are in early clinical development.
The report includes a compilation of currently active projects in research and development of small molecules, antibodies, proteins and vaccines targeting targeting the Notch pathway for treatment of cancer. In addition, the report lists company-specific R&D pipelines of Notch Pathway Inhibitors. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Product Category,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
- Notch Pathway Inhibitors
- Corporate Notch Pathway Inhibitor R&D Pipelines
- About La Merie
About Competitor Analysis Series
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.